Prostate Cancer | Clinical

Part 1: Guidelines and Recommendations for Treating nmCRPC

November 29, 2021

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

November 29, 2021

Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.

Mitigating Androgen Deprivation Therapy Cardiovascular Risk Factors in nmCRPC

November 22, 2021

Alicia K. Morgans, MD, PhD, discusses how to handle cardiovascular risk factors associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Sequencing Therapy for Metastatic Castration-Resistant Prostate Cancer

November 17, 2021

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

No-Shave November: The Benefits of the Transperineal Versus Transrectal Approach to Prostate Cancer Biopsy

November 16, 2021

Matthew J. Allaway, DO, discusses the need for a safe, precise and efficient option for performing prostate cancer biopsies via the transperineal approach and the limitations with the current standard of care, which is the transrectal approach, during No-Shave November awareness month.

Roundtable Discussion: Experts Look at Treatment Options for Patients With Metastatic Castration-Resistant Prostate Cancer

November 16, 2021

A 75-year-old man presented with intermittent right hip pain, but his physical examination was unremarkable and he had an ECOG performance score of 1. Two oncologists lead a discussion about the patient's case.

Carthon Discusses Testing and Chemotherapy Vs Targeted Therapy in CRPC

November 16, 2021

A group of oncologists led by Bradley C. Carthon, MD, PhD, discussed clinical work-up, treatment, and follow-up for a 75-year old patents with castration-resistant prostate cancer.

Apalutamide Added to SOC Improves Survival in Men With mCRPC

November 11, 2021

Over abiraterone/prednisone alone, apalutamide plus abiraterone-prednisone proves survival benefit in patients with metastatic castration resistant prostate cancer.

Part 3: Combining Therapies to Treat a Patient With CRPC

November 10, 2021

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

Unmet Needs and Key Takeaways in mCRPC

November 10, 2021

Matthew R. Smith, MD, PhD, discusses areas of unmet needs and clinical pearls for the management of patients with mCRPC.